Table 3.
Present drug treatment and vaccines of patients with COPD examined in function of the presence or the absence of associated heart disease
| Treatment | Patients without heart disease (n = 7,620) |
Patients with heart disease (n = 1,770) |
p |
|---|---|---|---|
| Short-action β2-adrenergic agonists (%) | 39.3 | 42.3 | NS |
| Long-action β2-adrenergic agonists (%) | 9.2 | 10.4 | NS |
| Anticholinergic drugs (%) | 83.9 | 88.6 | < 0.05 |
| Teophylline (%) | 11.3 | 15.6 | < 0.05 |
| Inhaled steroids (%) | 21.5 | 28.5 | < 0.05 |
| Oral steroids (%) | 5.3 | 7.4 | < 0.05 |
| Mucolytic drugs (%) | 8.5 | 10.2 | NS |
| Antiinfuenza vaccine during the previous campaign (%) | 86.7 | 91.0 | < 0.05 |
| Antipneumococcal vaccine at any time (%) | 31.6 | 39.2 | < 0.05 |
* All percentages and means have been adjusted to age and gender using the direct method.
NS: not significant.